| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/25/2000 | US6017512 Cyclic hexapeptides not comprised of a disulfide bond covalently linked to a radiolabel e.g. technetium; scintigraphic imaging agents; radiodiagnosis and -therapy; antitumor,-carcinogenic and -diabetic agents; stability |
| 01/25/2000 | US6017509 Cyclic hexapeptides not comprised of a disulfide bond covalently linked to a radiolabel e.g. technetium; scintigraphic imaging agents; radiodiagnosis and -therapy; antitumor,-carcinogenic and -diabetic agents; stability |
| 01/25/2000 | CA2027629C Glycopeptide antibiotics |
| 01/20/2000 | WO2000003036A1 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 01/20/2000 | WO2000003027A1 Method for improving the gene transfer of genetic material in mammalian cells through the use of p21 (waf-1) |
| 01/20/2000 | WO2000003018A2 Antibiotic protein and method of production |
| 01/20/2000 | WO2000003016A1 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 01/20/2000 | WO2000003015A2 Human transport protein homologs |
| 01/20/2000 | WO2000003014A1 Pharmaceutical uses of nab1 and nab2 |
| 01/20/2000 | WO2000003005A2 Human checkpoint kinase |
| 01/20/2000 | WO2000003004A2 Presenilin 2 specific ribozyme |
| 01/20/2000 | WO2000002924A1 Papillomavirus cellular receptor |
| 01/20/2000 | WO2000002920A1 Inhibition of lipoprotein formation |
| 01/20/2000 | WO2000002919A1 Growth hormone secretagogue related receptors and nucleic acids |
| 01/20/2000 | WO2000002917A2 Compounds and methods for modulating cadherin-mediated functions |
| 01/20/2000 | WO2000002916A2 PEPTIDE COMPOSITIONS MIMICKING TGF-β ACTIVITY |
| 01/20/2000 | WO2000002915A1 Compound capable of inhibiting the binding of a protein to mast cells, use of the compound for the preparation of a drug, a pharmaceutical composition, a method of diagnosing a disease, and a method of selection |
| 01/20/2000 | WO2000002913A1 Chemotaxis-inhibiting protein of staphylococcus (chips) and its use |
| 01/20/2000 | WO2000002912A2 Disintegrin homologs |
| 01/20/2000 | WO2000002911A2 INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON) |
| 01/20/2000 | WO2000002909A2 Amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins |
| 01/20/2000 | WO2000002908A2 Inhibition of alopecia |
| 01/20/2000 | WO2000002907A1 Tumor antigen peptide originating in sart-1 |
| 01/20/2000 | WO2000002906A1 Dolastatin 15 derivatives |
| 01/20/2000 | WO2000002905A2 Methods for accelerating bone and cartilage growth and repair |
| 01/20/2000 | WO2000002904A1 Matrix metalloproteinase inhibitors containing aminomalonic acid derivatives and peptide backbone modified derivatives thereof |
| 01/20/2000 | WO2000002902A1 Novel inhibitors of angiogenesis and tumor growth |
| 01/20/2000 | WO2000002898A1 Processes for coupling amino acids using bis-(trichloromethyl) carbonate |
| 01/20/2000 | WO2000002897A2 Delta cleavage products and methods based thereon |
| 01/20/2000 | WO2000002860A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 01/20/2000 | WO2000002590A1 Radiation and nanoparticles for enhancement of drug delivery in solid tumors |
| 01/20/2000 | WO2000002589A1 Modulation of haemopoietic cell activity and agents useful for same |
| 01/20/2000 | WO2000002584A2 Cancer treatment methods using antibodies to aminophospholipids |
| 01/20/2000 | WO2000002582A2 Treatment of celiac disease with interleukin-15 antagonists |
| 01/20/2000 | WO2000002581A1 Antigenic peptides derived from telomerase |
| 01/20/2000 | WO2000002580A2 Therapies using hemoproteins |
| 01/20/2000 | WO2000002579A2 Component b as angiogenic agent in combination with human growth factors |
| 01/20/2000 | WO2000002578A1 Remedies for apoptosis-associated diseases |
| 01/20/2000 | WO2000002577A1 Therapeutic use of uncoupling protein hhfcw60 |
| 01/20/2000 | WO2000002576A2 Egf-genistein for prevention of restenosis |
| 01/20/2000 | WO2000002575A1 Prion protein and uses thereof |
| 01/20/2000 | WO2000002574A1 Powdery preparation for mucosal administration containing polymeric medicine |
| 01/20/2000 | WO2000002558A1 Use of prenyltransferase inhibitors for preparing a medicine for treating pathologies resulting from heterotrimeric g protein membrane fixation |
| 01/20/2000 | WO2000002553A1 Compositions and methods for treating and preventing bone diseases using tocotrienols |
| 01/20/2000 | WO2000002548A2 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 01/20/2000 | WO1999060117A3 Prax-1 polypeptide |
| 01/20/2000 | WO1999059633A8 Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody |
| 01/20/2000 | WO1999059610A3 Use of lipopeptides or lipoproteins for wound treatment |
| 01/20/2000 | WO1999059541A3 Cyclosporin preparations |
| 01/20/2000 | WO1999059526A3 Protease inhibitors |
| 01/20/2000 | WO1999058676A3 Semaphorin polypeptides |
| 01/20/2000 | WO1999058641A8 Nt2lp, novel g-protein coupled receptors having homology to neurotensin-2 receptors |
| 01/20/2000 | WO1999058560A3 Prostapin gene and protein and uses thereof |
| 01/20/2000 | WO1999058559A3 Factors affecting tumor necrosis factor receptor releasing enzyme activity |
| 01/20/2000 | WO1999053943A3 Therapeutic angiogenic factors and methods for their use |
| 01/20/2000 | WO1999052544A3 Regulation of ovarian maturation and function using epidermal growth factor |
| 01/20/2000 | WO1999051742A3 Dadd, death activator death domain protein |
| 01/20/2000 | WO1999050289A3 Transformation progression-related genes and their use |
| 01/20/2000 | WO1999049037A3 Protein phosphatase-related molecules |
| 01/20/2000 | WO1999047674A3 Compounds and methods for therapy and diagnosis of lung cancer |
| 01/20/2000 | WO1999047150A3 A pharmaceutical composition containing ezrin mutated on tyrosine 353 |
| 01/20/2000 | WO1999040115A9 COMPOSITIONS AND METHODS TO INHIBIT FORMATION OF THE C5b-9 COMPLEX OF COMPLEMENT |
| 01/20/2000 | WO1999038964A3 Promoter regions of the mouse and human telomerase rna component genes |
| 01/20/2000 | CA2748996A1 Antigenic peptides derived from telomerase |
| 01/20/2000 | CA2343746A1 Therapeutic agents for apoptosis-related diseases |
| 01/20/2000 | CA2337438A1 Novel inhibitors of angiogenesis and tumor growth |
| 01/20/2000 | CA2337261A1 Use of prenyltransferase inhibitors for preparing a medicine for treating pathologies resulting from heterotrimeric g protein membrane fixation |
| 01/20/2000 | CA2337258A1 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them |
| 01/20/2000 | CA2337101A1 Papillomavirus cellular receptor |
| 01/20/2000 | CA2337060A1 Therapies using hemoproteins |
| 01/20/2000 | CA2336805A1 Pharmaceutical uses of nab1 and nab2 |
| 01/20/2000 | CA2335382A1 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 01/20/2000 | CA2335090A1 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 01/20/2000 | CA2334168A1 Inhibition of alopecia |
| 01/20/2000 | CA2334076A1 Processes for coupling amino acids using bis-(trichloromethyl) carbonate |
| 01/20/2000 | CA2334043A1 Antibiotic protein and method of production |
| 01/20/2000 | CA2333928A1 Compounds and methods for modulating cadherin-mediated functions |
| 01/20/2000 | CA2333923A1 Treatment of celiac disease with interleukin-15 antagonists |
| 01/20/2000 | CA2333898A1 Chemotaxis-inhibiting protein of staphylococcus (chips) and its use |
| 01/20/2000 | CA2333893A1 Delta cleavage products and methods based thereon |
| 01/20/2000 | CA2333857A1 Growth hormone secretagogue related receptors and nucleic acids |
| 01/20/2000 | CA2333855A1 Isolated amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins |
| 01/20/2000 | CA2332641A1 Dolastatin 15 derivatives |
| 01/20/2000 | CA2332625A1 Interaction of human beta amyloid precursor protein (.beta.-app) with human lon-protease like protein (hslon) |
| 01/20/2000 | CA2332568A1 Tumor antigen peptide originating in sart-1 |
| 01/20/2000 | CA2332497A1 Presenilin 2 specific ribozyme |
| 01/20/2000 | CA2332311A1 Disintegrin homologs |
| 01/20/2000 | CA2332307A1 Human transport protein homologs |
| 01/19/2000 | EP0972837A2 Ubiquitin specific protease like protein |
| 01/19/2000 | EP0972831A1 Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer |
| 01/19/2000 | EP0972782A1 Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it |
| 01/19/2000 | EP0972781A1 Proteins polypeptides and uses thereof |
| 01/19/2000 | EP0972780A1 Il-6 antagonist peptides |
| 01/19/2000 | EP0972779A2 Oligonucleotide-polyamide conjugates |
| 01/19/2000 | EP0972524A1 Lymphocyte activation inhibitors |
| 01/19/2000 | EP0972522A1 Anti-inflammatory composition |
| 01/19/2000 | EP0972521A1 Pharmaceutical composition containing stimulators of interferon-gamma |
| 01/19/2000 | EP0972520A1 Freeze-dried composition of bone morphogenetic protein human mp52 |
| 01/19/2000 | EP0972511A1 Association of a retinoid with a histidine derivative |
| 01/19/2000 | EP0972508A1 Extracellular matrix production promoter |